MedTrace Logo

A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06007482 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-06-23

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES009 administered intravenously to subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

ES009

ES009 is administered via intravenous infusion, once every 21 days.

Sponsors & Collaborators

  • Elpiscience Biopharma Australia Pty. Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-26
Primary Completion
2025-02-18
Completion
2025-02-18

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06007482 on ClinicalTrials.gov